{"id":"i131","safety":{"commonSideEffects":[{"rate":null,"effect":"Salivary gland dysfunction"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Secondary malignancy risk"},{"rate":null,"effect":"Hypothyroidism"}]},"_chembl":{"chemblId":"CHEMBL3677816","moleculeType":"Small molecule","molecularWeight":"404.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"I-131 is taken up selectively by thyroid follicular cells and other tissues expressing the sodium-iodide symporter, delivering targeted radiation that destroys cancer cells while sparing surrounding tissue. The beta particles emitted have a short range (typically a few millimeters), allowing localized cell killing. This approach is particularly effective for differentiated thyroid cancers and metastases that retain iodine-uptake capacity.","oneSentence":"Iodine-131 is a radioactive isotope that emits beta particles to destroy thyroid cancer cells and other iodine-avid malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:17.926Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Differentiated thyroid cancer (papillary and follicular) with radioactive iodine-avid metastases"},{"name":"Thyroid cancer recurrence and metastatic disease"}]},"trialDetails":[{"nctId":"NCT02152995","phase":"PHASE2","title":"Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-08-14","conditions":"Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma","enrollment":34},{"nctId":"NCT02952508","phase":"PHASE2","title":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cellectar Biosciences, Inc.","startDate":"2017-07-26","conditions":"Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia","enrollment":120},{"nctId":"NCT05610891","phase":"PHASE1","title":"Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cellectar Biosciences, Inc.","startDate":"2023-10-01","conditions":"High-Grade Glioma","enrollment":50},{"nctId":"NCT03478462","phase":"PHASE1","title":"Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cellectar Biosciences, Inc.","startDate":"2019-04-30","conditions":"Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor","enrollment":30},{"nctId":"NCT00006721","phase":"PHASE3","title":"S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-03","conditions":"Lymphoma","enrollment":571},{"nctId":"NCT00107289","phase":"PHASE2","title":"Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-05","conditions":"Neuroblastoma, Pheochromocytoma","enrollment":200},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT03841617","phase":"PHASE2","title":"The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2019-07-29","conditions":"Thyroid Cancer","enrollment":30},{"nctId":"NCT04512716","phase":"EARLY_PHASE1","title":"Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-02","conditions":"B-ALL, DLBCL, B ALL","enrollment":12},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT06440850","phase":"PHASE2","title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-15","conditions":"Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma","enrollment":21},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT07353333","phase":"NA","title":"Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-01-30","conditions":"HCC, SPECT-CT","enrollment":6},{"nctId":"NCT01783288","phase":"NA","title":"Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2013-02","conditions":"Postural Tachycardia Syndrome","enrollment":110},{"nctId":"NCT07311993","phase":"PHASE1","title":"Phase 1 Study of CLR 125 in Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Cellectar Biosciences, Inc.","startDate":"2025-12-05","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT06980103","phase":"NA","title":"Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2025-08-06","conditions":"Thyroid Cancer","enrollment":408},{"nctId":"NCT07314255","phase":"","title":"The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2025-12-18","conditions":"PTC, I-131, Trop2","enrollment":60},{"nctId":"NCT03128034","phase":"PHASE1, PHASE2","title":"211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2017-10-24","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT01850888","phase":"NA","title":"MIBG for Refractory Neuroblastoma and Pheochromocytoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-12","conditions":"Relapsed Neuroblastoma, Metastatic Pheochromocytoma","enrollment":15},{"nctId":"NCT07261241","phase":"PHASE2","title":"NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab","status":"NOT_YET_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2026-07-31","conditions":"Neuroblastoma","enrollment":118},{"nctId":"NCT02725060","phase":"NA","title":"Autoimmune Basis for Postural Tachycardia Syndrome","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2016-02","conditions":"Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, Tachycardia","enrollment":58},{"nctId":"NCT02914405","phase":"PHASE1","title":"Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2018-05-24","conditions":"Neuroblastoma","enrollment":44},{"nctId":"NCT03517579","phase":"NA","title":"Personalized Treatment in Thyroid Disorders","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-12-11","conditions":"Thyroid Cancer, Graves Disease","enrollment":10},{"nctId":"NCT04290663","phase":"PHASE3","title":"Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up","status":"RECRUITING","sponsor":"Centre Francois Baclesse","startDate":"2020-03-02","conditions":"Thyroid Cancer, Intermediate Risk","enrollment":476},{"nctId":"NCT03939689","phase":"PHASE2","title":"I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).","status":"COMPLETED","sponsor":"Progenics Pharmaceuticals, Inc.","startDate":"2019-05-30","conditions":"Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm","enrollment":120},{"nctId":"NCT00673010","phase":"PHASE1","title":"Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2005-03-07","conditions":"Thyroid Cancer","enrollment":20},{"nctId":"NCT00608725","phase":"NA","title":"Pathophysiology of Orthostatic Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Satish R. Raj","startDate":"1996-12","conditions":"Tachycardia, Postural Orthostatic Tachycardia Syndrome","enrollment":260},{"nctId":"NCT07157514","phase":"PHASE2, PHASE3","title":"Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2026-01","conditions":"Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia","enrollment":306},{"nctId":"NCT03165292","phase":"PHASE2","title":"Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-10-01","conditions":"Very High Risk Neuroblastoma","enrollment":34},{"nctId":"NCT04105543","phase":"PHASE1","title":"CLR 131 Combined With Radiation for Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-12-20","conditions":"Head and Neck Cancer","enrollment":12},{"nctId":"NCT05064306","phase":"","title":"131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults","status":"NO_LONGER_AVAILABLE","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"","conditions":"Central Nervous System/Leptomeningeal Neoplasms","enrollment":""},{"nctId":"NCT01163383","phase":"","title":"131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol","status":"AVAILABLE","sponsor":"John Maris","startDate":"","conditions":"Neuroblastoma, Childhood Metastatic Pheochromocytoma","enrollment":""},{"nctId":"NCT04022213","phase":"PHASE2","title":"A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-07-15","conditions":"Desmoplastic Small Round Cell Tumor, Peritoneal Cancer, Peritoneal Carcinoma","enrollment":31},{"nctId":"NCT03215095","phase":"EARLY_PHASE1","title":"RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-07-10","conditions":"Thyroid Cancer","enrollment":11},{"nctId":"NCT05142904","phase":"PHASE3","title":"Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules","status":"TERMINATED","sponsor":"Rijnstate Hospital","startDate":"2021-11-17","conditions":"Thyroid Nodule, Toxic or With Hyperthyroidism, Autonomous Thyroid Function, Thyroid Nodule; Hyperthyroidism","enrollment":40},{"nctId":"NCT07015684","phase":"PHASE1","title":"131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-04-28","conditions":"Sickling Disorder Due to Hemoglobin S","enrollment":24},{"nctId":"NCT02378428","phase":"PHASE2","title":"MIBG Therapy for Patients With MIBG Avid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2014-03-01","conditions":"MIBG Avid Tumors","enrollment":65},{"nctId":"NCT06768905","phase":"PHASE1, PHASE2","title":"Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-04-25","conditions":"Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":30},{"nctId":"NCT00135200","phase":"PHASE2","title":"Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2005-08","conditions":"Multiple Myeloma","enrollment":16},{"nctId":"NCT00381641","phase":"PHASE2","title":"Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-08-29","conditions":"Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma","enrollment":63},{"nctId":"NCT06000787","phase":"NA","title":"MCT for the Harvard/UCSF ROBIN Center","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-09-19","conditions":"Glioma, Childhood Brainstem, Neuroblastoma","enrollment":47},{"nctId":"NCT05668962","phase":"PHASE2","title":"Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-03-01","conditions":"Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer","enrollment":30},{"nctId":"NCT03649438","phase":"","title":"131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma","status":"NO_LONGER_AVAILABLE","sponsor":"University of Texas Southwestern Medical Center","startDate":"","conditions":"Relapsed Neuroblastoma, Metastatic Pheochromocytoma","enrollment":""},{"nctId":"NCT02393690","phase":"PHASE2","title":"Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2015-05-04","conditions":"Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma","enrollment":60},{"nctId":"NCT03015844","phase":"","title":"A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma","status":"AVAILABLE","sponsor":"Northwell Health","startDate":"","conditions":"Neuroblastoma, Pheochromocytoma","enrollment":""},{"nctId":"NCT05713123","phase":"NA","title":"Comparison of Record in VERITON Camera to the Anger Camera Procedure in Patients Treated by 131-iodine","status":"RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2022-12-26","conditions":"Device","enrollment":77},{"nctId":"NCT01398085","phase":"PHASE2, PHASE3","title":"IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2012-05","conditions":"Thyroid Cancer","enrollment":504},{"nctId":"NCT04614766","phase":"PHASE1, PHASE2","title":"A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors","status":"WITHDRAWN","sponsor":"David Bushnell","startDate":"2022-09-30","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT00445965","phase":"PHASE2","title":"Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-01","conditions":"Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer","enrollment":78},{"nctId":"NCT04354324","phase":"NA","title":"Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2020-04-20","conditions":"Papillary Thyroid Cancer","enrollment":254},{"nctId":"NCT03275402","phase":"PHASE2, PHASE3","title":"131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases","status":"TERMINATED","sponsor":"Y-mAbs Therapeutics","startDate":"2018-12-11","conditions":"Neuroblastoma, CNS Metastases, Leptomeningeal Metastases","enrollment":52},{"nctId":"NCT00089245","phase":"PHASE1","title":"Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer","status":"TERMINATED","sponsor":"Y-mAbs Therapeutics","startDate":"2004-02-05","conditions":"Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma","enrollment":177},{"nctId":"NCT00415233","phase":"PHASE3","title":"High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer","status":"UNKNOWN","sponsor":"University College, London","startDate":"2006-11","conditions":"Head and Neck Cancer","enrollment":438},{"nctId":"NCT06028282","phase":"","title":"Post-RAI Therapy Dosimetry and Quality Assessment of Target Tissue Dosing","status":"UNKNOWN","sponsor":"State University of New York - Upstate Medical University","startDate":"2021-11-08","conditions":"Thyroid Disease","enrollment":10},{"nctId":"NCT00509353","phase":"PHASE1","title":"N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2007-01","conditions":"Neuroblastoma","enrollment":26},{"nctId":"NCT05182931","phase":"PHASE2","title":"A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)","status":"UNKNOWN","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2022-07-14","conditions":"Thyroid Cancer","enrollment":80},{"nctId":"NCT04964284","phase":"PHASE3","title":"Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer","status":"UNKNOWN","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2021-10-06","conditions":"Differentiated Thyroid Cancer","enrollment":328},{"nctId":"NCT04858867","phase":"NA","title":"Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2022-01-10","conditions":"Differentiated Thyroid Cancer","enrollment":12},{"nctId":"NCT00003102","phase":"PHASE1, PHASE2","title":"Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"1998-11-17","conditions":"Kidney Cancer","enrollment":15},{"nctId":"NCT04855097","phase":"NA","title":"Evaluation of Blood Volume Analysis- Guided Management of Decompensated Heart Failure","status":"COMPLETED","sponsor":"Daxor Corporation","startDate":"2022-05-01","conditions":"Acute Decompensated Heart Failure","enrollment":32},{"nctId":"NCT00006695","phase":"PHASE2","title":"Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2000-04-01","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT01838187","phase":"","title":"Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma","status":"NO_LONGER_AVAILABLE","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"","conditions":"Neuroblastoma, Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT04391244","phase":"","title":"Investigating National Solutions for Personalised Iodine-131 Radiation Exposure","status":"UNKNOWN","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2020-06-17","conditions":"Differentiated Thyroid Cancer","enrollment":150},{"nctId":"NCT03044977","phase":"EARLY_PHASE1","title":"Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Bushnell","startDate":"2017-05-07","conditions":"Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting","enrollment":20},{"nctId":"NCT01484093","phase":"PHASE1, PHASE2","title":"Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-11-29","conditions":"Mantle Cell Lymphoma","enrollment":96},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":"Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute","enrollment":153},{"nctId":"NCT02432274","phase":"PHASE1, PHASE2","title":"Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2014-12-29","conditions":"Tumors, Solid Malignant Tumors, Osteosarcoma","enrollment":117},{"nctId":"NCT05063357","phase":"PHASE1","title":"131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma","status":"WITHDRAWN","sponsor":"Y-mAbs Therapeutics","startDate":"2022-03","conditions":"DIPG","enrollment":""},{"nctId":"NCT01837745","phase":"PHASE3","title":"Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2013-05-13","conditions":"Low Risk Differentiated Thyroid Cancer","enrollment":776},{"nctId":"NCT00788307","phase":"PHASE1","title":"Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2008-11-03","conditions":"Prostate Cancer","enrollment":8},{"nctId":"NCT00253435","phase":"PHASE2","title":"N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2005-09","conditions":"Neuroblastoma","enrollment":50},{"nctId":"NCT01019850","phase":"PHASE1","title":"N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2010-03","conditions":"Neuroblastoma","enrollment":27},{"nctId":"NCT04776993","phase":"PHASE3","title":"A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy","status":"UNKNOWN","sponsor":"University of Pisa","startDate":"2023-03-02","conditions":"Graves' Orbitopathy","enrollment":52},{"nctId":"NCT04922801","phase":"","title":"Optimising Molecular Radionuclide Therapy","status":"COMPLETED","sponsor":"King's College London","startDate":"2021-12-09","conditions":"Neuroendocrine Tumors, Hyperthyroidism, Thyroid Cancer","enrollment":50},{"nctId":"NCT01590680","phase":"","title":"Expanded Access Protocol Using 131I-MIBG","status":"AVAILABLE","sponsor":"Jubilant DraxImage Inc.","startDate":"","conditions":"Neuroblastoma, Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT02278315","phase":"PHASE1","title":"Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Cellectar Biosciences, Inc.","startDate":"2015-02","conditions":"Multiple Myeloma","enrollment":31},{"nctId":"NCT03561259","phase":"PHASE2","title":"A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects","status":"UNKNOWN","sponsor":"Jubilant DraxImage Inc.","startDate":"2019-10-21","conditions":"Neuroblastoma, Neuroectodermal Tumors, Neoplasms","enrollment":60},{"nctId":"NCT00589316","phase":"PHASE1","title":"Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2007-10-05","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":26},{"nctId":"NCT04156854","phase":"NA","title":"Intravascular Volume Expansion to Neuroendocrine-Renal Function Profiles in Chronic Heart Failure","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-01-30","conditions":"Heart Failure","enrollment":15},{"nctId":"NCT02773667","phase":"","title":"Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine","status":"COMPLETED","sponsor":"Jena University Hospital","startDate":"2016-01","conditions":"Thyroid Carcinoma","enrollment":83},{"nctId":"NCT04770831","phase":"","title":"Patients Who Receive 131 I-MIBG","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2021-03-10","conditions":"Brain and Nervous System","enrollment":""},{"nctId":"NCT00119366","phase":"PHASE2","title":"Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2003-05","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":18},{"nctId":"NCT03506048","phase":"PHASE2","title":"Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer","status":"TERMINATED","sponsor":"Emory University","startDate":"2019-01-16","conditions":"Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma","enrollment":4},{"nctId":"NCT05468554","phase":"PHASE3","title":"Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2022-11-01","conditions":"Thyroid Cancer","enrollment":160},{"nctId":"NCT00291486","phase":"PHASE1","title":"Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2003-10","conditions":"Colorectal Neoplasms","enrollment":19},{"nctId":"NCT03427320","phase":"PHASE1, PHASE2","title":"Imaging of Advanced Tumours Using [131]I-IAZA","status":"WITHDRAWN","sponsor":"University of Alberta","startDate":"2018-12","conditions":"Locally Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":""},{"nctId":"NCT00454220","phase":"PHASE2","title":"Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-07","conditions":"Multinodular Goiter","enrollment":96},{"nctId":"NCT04009863","phase":"NA","title":"HIFU Ablation vs Fixed-dose RAI-131 Therapy in Moderate-sized Non-toxic MNG","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2020-04-01","conditions":"Non Toxic Multinodular Goiter, High Intensity Focused Ultrasound, RAI","enrollment":156},{"nctId":"NCT04831567","phase":"PHASE2","title":"Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors","status":"WITHDRAWN","sponsor":"AC Camargo Cancer Center","startDate":"2021-02-04","conditions":"Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT05299437","phase":"PHASE2","title":"Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry","status":"UNKNOWN","sponsor":"Carlo Chiesa","startDate":"2021-05-12","conditions":"Metastatic Differentiated Thyroid Cancer","enrollment":50},{"nctId":"NCT03349294","phase":"","title":"Clinical Study of Biokinetic Model of Iodine-131 in Total(Near) Thyroidectomy Patients.","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2017-11-01","conditions":"Thyroidectomy","enrollment":11},{"nctId":"NCT01547117","phase":"NA","title":"Dietary Salt in Postural Tachycardia Syndrome","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2012-03","conditions":"Postural Orthostatic Tachycardia Syndrome","enrollment":38},{"nctId":"NCT04952493","phase":"PHASE2","title":"Anlotinib or Penpulimab in Combination With RAI for DTC","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-09-15","conditions":"Thyroid Cancer","enrollment":42},{"nctId":"NCT02966093","phase":"PHASE3","title":"A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2017-01-11","conditions":"Differentiated Thyroid Cancer (DTC)","enrollment":151},{"nctId":"NCT01563107","phase":"NA","title":"Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2012-03","conditions":"Postural Orthostatic Tachycardia Syndrome","enrollment":38},{"nctId":"NCT02731352","phase":"PHASE2","title":"Study of Apatinib in Patients With Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2016-03-11","conditions":"Thyroid Cancer","enrollment":20},{"nctId":"NCT02702388","phase":"PHASE2","title":"A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-06-08","conditions":"Thyroid Cancer","enrollment":241},{"nctId":"NCT00479167","phase":"PHASE2","title":"A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2007-05","conditions":"Follicular Lymphoma","enrollment":1},{"nctId":"NCT00329030","phase":"PHASE3","title":"Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-12","conditions":"Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Non-Hodgkin","enrollment":224},{"nctId":"NCT01208051","phase":"PHASE1, PHASE2","title":"Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-09","conditions":"Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Hurthle Cell Carcinoma","enrollment":127}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"DACRYOSTENOSIS ACQUIRED"},{"count":4,"reaction":"LACRIMATION INCREASED"},{"count":3,"reaction":"HYPOTHYROIDISM"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"VENOOCCLUSIVE LIVER DISEASE"},{"count":1,"reaction":"ABDOMINAL DISCOMFORT"},{"count":1,"reaction":"AREFLEXIA"},{"count":1,"reaction":"ATRIAL FIBRILLATION"},{"count":1,"reaction":"BLOOD CALCIUM DECREASED"},{"count":1,"reaction":"BLOOD POTASSIUM DECREASED"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["low dose RAI"],"phase":"phase_3","status":"active","brandName":"I131","genericName":"I131","companyName":"Gustave Roussy, Cancer Campus, Grand Paris","companyId":"gustave-roussy-cancer-campus-grand-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iodine-131 is a radioactive isotope that emits beta particles to destroy thyroid cancer cells and other iodine-avid malignancies. Used for Differentiated thyroid cancer (papillary and follicular) with radioactive iodine-avid metastases, Thyroid cancer recurrence and metastatic disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}